ME VS CNCE Stock Comparison

Performance

ME
10/100

ME returned -75.03% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

CNCE
100/100

CNCE returned 186.64% in the last 12 months. Based on the other stocks in it's sector with an average return of -22.72%, it's performance is above average giving it a grade of 100 of 100.

Technicals

ME
36/100

ME receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

CNCE
64/100

CNCE receieves a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

ME
10/100

ME has missed earnings 5 times in the last 20 quarters.

CNCE
10/100

CNCE has missed earnings 8 times in the last 20 quarters.

Profit

ME
10/100

Out of the last 14 quarters, ME has had 0 profitable quarters and has increased their profits year over year on 0 of them.

CNCE
10/100

Out of the last 18 quarters, CNCE has had 3 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

ME
45/100

ME has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

CNCE
58/100

CNCE has had a higher than average amount of volatility over the last 12 months giving it a grade of 57 of 100.

Forecast

ME

"Forecast" not found for ME

CNCE
80/100

5 analysts offer 12-month price forecasts for CNCE. Together, they have an average target of 0, the most optimistic forecast put CNCE at 0 within 12-months and the most pessimistic has CNCE at 0.

Sentiment

ME

"Sentiment" not found for ME

CNCE
69/100

CNCE had a bullish sentiment score of 68.54% across Twitter and StockTwits over the last 12 months. It had an average of 7.29 posts, 0.27 comments, and 2.20 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

23andMe Holding Co. Class A Common Stock Summary

Nasdaq / ME

Healthcare

Medical - Diagnostics & Research

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

Concert Pharmaceuticals, Inc. Summary

Nasdaq / CNCE

Healthcare

Biotechnology

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Power up your portfolio